NCT00099541

Non-small Cell Lung Cancer Registry

A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions develop. This trial is seeking patients 18 years or older that have been diagnosed with Stage IIIB or Stage IV non-small cell lung cancer that cannot be treated by surgery.

Conditions

• Non-Small-Cell Lung Cancer
• Pleural Effusion, Malignant

Interventions

Type	Name	Description
DRUG	zoledronic acid

Timeline

• Start date: 2004-11-01
• Completion: 2007-11-01
• First posted: 2004-12-16
• Last updated: 2009-11-23

Locations

101 sites across 1 country: United States